Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
KP-1077 by Zevra Therapeutics for Idiopathic Hypersomnia (IH): Likelihood of Approval
KP-1077 is under clinical development by Zevra Therapeutics and currently in Phase II for Idiopathic Hypersomnia (IH). According to GlobalData,...
Data Insights
KP-1077 by Zevra Therapeutics for Narcolepsy: Likelihood of Approval
KP-1077 is under clinical development by Zevra Therapeutics and currently in Phase II for Narcolepsy. According to GlobalData, Phase II...